After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...
CTS will be revising some forms in use by clients on October 26, 2020. We do try to limit form chang...
That’s just one of the reasons that National Blood Donor Month, which has taken place each Jan...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...
CTS Charlotte Lab successfully implemented WNV NAT testing on the Panther Testing Platform on Monday...